HomeClinical TopicsCardio-PulmonaryFDA approves Brilinta for ACSs

FDA approves Brilinta for ACSs

The U.S. Food and Drug Administration (FDA) has approved Brilinta (ticarelor) for reducing cardiovascular death and heart attack in patients with acute coronary syndromes (ACSs). Read more..

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content